MAREZINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAREZINE is an injectable small-molecule product approved by GSK in 1954 for an undisclosed indication. The specific mechanism of action and therapeutic uses are not documented in available data.
LOE Approaching
Legacy product nearing loss of exclusivity with minimal current commercial investment and likely reduced team size.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MAREZINE offers limited career growth given its LOE-approaching status and zero linked job openings. This role suits professionals seeking stable, legacy product management or those early in their career accepting lower-profile assignments.
Brand ManagerProduct Manager
Worked on MAREZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.